Ask AI
ProCE Banner Activity

DESTINY-Breast11: Safety Analysis of Neoadjuvant T-DXd With or Without THP vs ddAC-THP in Patients With High-Risk HER2+ EBC

Conference Coverage
Slideset

In-depth safety analysis of phase III DESTINY-Breast11 showed that neoadjuvant treatment with T-DXd–THP was associated with lower rates of grade 3 or higher ILD/pneumonitis and ventricular dysfunction than ddAC-THP in high-risk, HER2+ early breast cancer.

Released: December 18, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify subpopulations of patients with breast cancer most likely to benefit from a specific treatment plan based on predictive biomarkers

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with breast cancer
  • Evaluate new data on novel agents and therapeutic approaches for patients with breast cancer